Document Detail


Trypanosoma cruzi: the role of PGE2 in immune response during the acute phase of experimental infection.
MedLine Citation:
PMID:  18163990     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chagas disease is characterized by cardiac lesions and a high level of PGE2. Our objective was to investigate the role of PGE2 in cardiac lesions. BALB/c mice were infected with Trypanosoma cruzi (1x10(3) trypomastigote forms) and were treated daily with PBS, meloxicam (0.5 mg/kg) or etoricoxib (0.6 mg/kg). The animals were sacrificed on the 21st day of infection and we collected the cardiac tissue and spleen cells for tissue culture. We observed that treatment with COX-2 inhibitors was able to decrease synthesis of PGE2 by spleen cells. This reduction was accompanied by reduction of the inflammatory infiltrate, parasite nets, cardiac fibrosis and fewer COX-2 positive cells in cardiac tissue obtained from these animals. In conclusion, treatment with COX-2 inhibitors, and consequent inhibition of PGE2 synthesis, was able to reduce the cardiac damage observed during the acute phase of experimental Chagas disease, thus demonstrating the involvement of this mediator in the cardiac lesion.
Authors:
G K Abdalla; G E L Faria; K T Silva; E C C Castro; M A Reis; M A Michelin
Publication Detail:
Type:  Journal Article     Date:  2007-11-17
Journal Detail:
Title:  Experimental parasitology     Volume:  118     ISSN:  0014-4894     ISO Abbreviation:  Exp. Parasitol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-17     Completed Date:  2008-05-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370713     Medline TA:  Exp Parasitol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  514-21     Citation Subset:  IM    
Affiliation:
Laboratory of Immunology, Federal University of Triângulo Mineiro, Rua Frei Paulino, 30, 38 025-180 Uberaba, MG, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Animals
Cells, Cultured
Chagas Disease / drug therapy,  immunology*,  pathology
Cyclooxygenase 1 / analysis
Cyclooxygenase 2 / analysis
Cyclooxygenase Inhibitors / therapeutic use
Dinoprostone / biosynthesis,  physiology*
Fibrosis
Male
Mice
Mice, Inbred BALB C
Myocardium / enzymology,  pathology
Parasitemia / drug therapy,  parasitology
Prostaglandins / analysis
Pyridines / therapeutic use
Spleen / chemistry,  cytology
Sulfones / therapeutic use
Thiazines / therapeutic use
Thiazoles / therapeutic use
Trypanosoma cruzi / immunology*
Chemical
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Prostaglandins; 0/Pyridines; 0/Sulfones; 0/Thiazines; 0/Thiazoles; 202409-33-4/etoricoxib; 363-24-6/Dinoprostone; 71125-38-7/meloxicam; EC 1.14.99.1/Cyclooxygenase 1; EC 1.14.99.1/Cyclooxygenase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Retinoid processing in cone and Müller cell lines.
Next Document:  Gene expression in women conceiving spontaneously over the age of 45 years.